TY - JOUR T1 - Is India heading towards a new high? : An optimistic approach to estimate ending life-cycle and cumulative cases by the end of the major COVID-19 pandemic wave in India and some of its states JF - medRxiv DO - 10.1101/2020.05.30.20117440 SP - 2020.05.30.20117440 AU - P. Gupta AU - K. K. Sharma AU - S.D. Joshi AU - S. Goyal Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/04/2020.05.30.20117440.abstract N2 - Projecting the COVID-19 curve parameters such as ending-lifecycle and cumulative cases are helpful in guiding the policy makers to mitigate the outbreak. However, overestimating these parameters may put the public and policy makers in a muddle. In this paper, an optimistic scenario is simulated, wherein the dynamics of the COVID-19 curve is allowed to spread to such an extent that the projections of the COVID-19 parameters do not take excessively high values. Based on this scenario, the ending life-cycle and cumulative cases for India and some of its states, are predicted. Our study, suggests that the fall of the peak amplitude (95%) of the major COVID-19 wave in India may take place by the 8th of September 2020 with a total count of 655000 cases. Simulation results, also indicate that Maharashtra, Tamil Nadu, Delhi, Gujarat, Uttar Pradesh, Bihar, Madhya Pradesh, and Rajasthan may end up with 263700, 18140, 50600, 21130, 24420, 44170, 27080, and 28200 cumulative cases respectively.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study is not a clinical trialFunding StatementWe did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:It is not a study on a human subjects.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yeswe obtained the data from the labnol website. The data is fetched from the MoHFW website. https://www.labnol.org/code/covid-19-india-tracker-200325 ER -